Tokyo Big Sight

Nov 13, 2016 9:30 AM - Nov 15, 2016 5:30 PM

3-11-1 Ariake, Koto-ku, Tokyo, 135-0063 Japan

13th DIA Japan Annual Meeting 2016

Overview

Online Registration has been closed. Onsite Registration will be available at Tokyo Big Sight.

Click Here to View the Program.

Among the major issues in recent new medicine development, problems such as species differences when extrapolating non-clinical study results to humans and the differences between clinical trial subjects and actual patients when we apply clinical trial results to patients in clinical practice, stand out as challenges which must be overcome in regulatory science research which aims for the proper utilization of medicines considering each patient’s individual risks.


Recent technological progresses in the medicine and pharmacology are expected to provide powerful tools to overcome these barriers, and a longawaited platform that enables patient-engaged new medicine development is gradually being developed. For example, the human genetic code can be analyzed rapidly and at low cost due to the progress of genetic engineering, and searches of disease specific genes in patients’ clinical samples have accelerated. The discovery of iPS cells made it possible to study diseases by direct use of patient cells as well as to enhance new medicine development through screening for efficacy and safety in ways that were previously impossible. Simulation techniques for physiologic and disease conditions have enabled better prediction, which was not possible in prior non-clinical and clinical trials. Moreover, there is the potential for gaining further information which can be applied to individual patients by pharmacoepidemiological research using the enormous quantity of data generated by clinical practice.


This year, Dr. Tatsuo Kurokawa will become the first Japanese President of  DIA. In this memorable year, we would like to provide a forum where academia, government and industry gather to discuss new scientific technologies which will provide breakthroughs for future regulatory science research at the DIA Japan Annual Meeting. It goes without saying that quality, efficacy and safety of medical products are supported by all stakeholders’ ethics and compliance. While the number of stakeholders is increasing due to the large scale of global medicine development, and the wide variety of people who are involved with these new technologies, we would like this meeting to be an opportunity to deeply consider our highest priority objective; ‘for patients’.

Featured

Want to learn more about 13th DIA Japan Annual Meeting 2016? You've come to the right site!

Continuing-Education

Exhibits

Program Committee

  • Yoshinobu  Hirayama, PhD
    Yoshinobu Hirayama, PhD Professor, College of Pharmaceutical Sciences
    Ritsumeikan University, Japan
  • Atsushi  Tsukamoto, PhD, MSc
    Atsushi Tsukamoto, PhD, MSc Head is Therapeutic Area Strategies
    Daiichi Sankyo, United States
  • Hiroyuki  Aono
    Hiroyuki Aono Senior Advisor, Research and Development Solutions Center of Excellence
    IQVIA Services Japan K.K., Japan
  • Yoshikata  Furuya, MSc
    Yoshikata Furuya, MSc Manager, General Affairs Division
    Sankeien Hoshoukai Foundation, Japan
  • Kanji  Hirai, RPh
    Kanji Hirai, RPh Director, Regulatory Policy & Intelligence, Regulatory Affair Area, Japan Dvlpmt
    MSD K.K., Japan
  • Akihiro  Hirakawa, PhD
    Akihiro Hirakawa, PhD Professor,Clinical Biostatistics,Graduate School of Medical and Dental Sciences
    Tokyo Medical and Dental University, Japan
  • Shinzo  Hiroi, PhD, MPH, RPh, PMP
    Shinzo Hiroi, PhD, MPH, RPh, PMP Senior Director, Project Management, IDC ICO Real World Solutions
    ICON Clinical Research GK, Japan
  • Chieko  Hirose, MSc
    Chieko Hirose, MSc Regulatory Coordination Officer
    Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Digital Learning Catalog

DIA Learning: eLearning Soultions
Download

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.